CSL Research Acceleration Initiative

Overview and Program Goals

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives.

CSL’s Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organizations. These partnerships provide funding and access to industry experts for scientists working on novel biotherapeutic strategies in CSL’s therapeutic areas. The 2023 Research Acceleration Initiative will focus on research proposals that align with a CSL Therapeutic Areas (listed below) and are amenable to or include a Modality listed below.

Successful applicants will receive up to $400,000 over two years.

Interested researchers are invited to join an online information session to learn more. Webinars will be held:

  • January 25, 2023 10:00am PT
  • February 6, 2023 1:00 pm PT

Download Full Announcement

Request Webinar Links & Application Instructions

Deadline: February 23, 2023

Researchers who wish to apply are required to submit a nonconfidential 300-word online abstract by February 23, 2023.

Eligibility

Applicant must be a UO faculty, postdoc, or student to apply.

Therapeutic Areas & Modalities

CSL is seeking applications that align with a CSL Therapeutic Area and are amenable to or include a CSL Modality in the following Focus Areas. Please download the full announcement for additional details.

  • Immunology
    • Autoimmune diseases
    • Alternatives to plasma-derived intravenous immunoglobulin
  • Cardiovascular and Metabolic
    • Myocarditis
    • Dilated cardiomyopathy
    • Rare lipid disorders
    • Severe forms of atherosclerosis
  • Oral Delivery
    • Technologies enabling oral delivery of biologics
  • Hematology
    • Hemorrhagic stroke
    • Acute ischemic stroke
    • Acute thrombosis
  • Transplant
    • Chronic lung allograft dysfunction
    • Hematopoietic stem cell transplant
    • Cardiovascular allograft vasculopathy
  • Respiratory
    • Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
    • Community acquired pneumonia-associated complications
  • Vaccines
    • mRNA and lipid nanoparticle platform
    • Influenza virus antigen purity and yield enhancement
    • Proven adjuvant technology
  • Gene Therapy